GSK-2879552

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H28N2O2
Molecular Weight	364.4806
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=C(CN2CCC(CN[C@@H]3C[C@H]3C4=CC=CC=C4)CC2)C=C1

InChI

InChIKey=LRULVYSBRWUVGR-FCHUYYIVSA-N

InChI=1S/C23H28N2O2/c26-23(27)20-8-6-18(7-9-20)16-25-12-10-17(11-13-25)15-24-22-14-21(22)19-4-2-1-3-5-19/h1-9,17,21-22,24H,10-16H2,(H,26,27)/t21-,22+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://adisinsight.springer.com/drugs/800039726 | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756742
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26175415

GSK2879552 – is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival. On October 2016 GlaxoSmithKline plans a phase I/II trial for Myelodysplastic syndromes (Monotherapy, Combination therapy, Second-line therapy or greater) in USA, Canada and Europe (PO) (NCT02929498).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Lysine-specific histone demethylase 1 7 Target ID: CHEMBL6136 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26175415 \| https://www.ncbi.nlm.nih.gov/pubmed/27769034	Inhibitor 8297		0.024 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Small-cell lung cancer 41 Sources: https://clinicaltrials.gov/ct2/show/NCT02034123 http://adisinsight.springer.com/drugs/800039726	Primary		Phase I 428	Unknown Approved Use Unknown
Acute myeloid leukemia 136 Sources: https://clinicaltrials.gov/ct2/show/NCT02177812 http://adisinsight.springer.com/drugs/800039726	Primary		Phase I 428	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P009CYS	https://www.1pchem.com/search?query=1P009CYS
A2B Chem	AE35908	http://a2bchem.com/prod/AE35908
AChemBlock	M15673	http://www.achemblock.com/catalogsearch/result/?q=M15673
Ambeed	A104072	http://www.ambeed.com/search/Search.html?keyword=A104072
Angene	AGN-PC-0WANGM	http://www.angenechemical.com/productshow/AGN-PC-0WANGM.html
ApexBio Technology	B5879	https://www.apexbt.com/catalogsearch/result/?q=B5879
AstaTech	40835	http://astatechinc.com/CPSResult.php?CRNO=40835
BLD Pharm	BD293255	http://www.bldpharm.com/search/Search.html?keyword=BD293255
Cayman Chemical	19403	http://www.caymanchem.com/app/template/Product.vm/catalog/19403
Chem Scene	CS-3997	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3997
ChemShuttle	140506	https://www.chemshuttle.com/catalogsearch/result/?q=140506
Combi-Blocks	QW-5510	http://www.combi-blocks.com/cgi-bin/find.cgi?QW-5510
KeyOrganics	AS-56180	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56180
Lab Network	LN01342467	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342467
MedChem Express	HY-18632	https://www.medchemexpress.com/search.html?q=HY-18632&ft=&fa=&fp=
MolPort	MolPort-044-183-470	https://www.molport.com/shop/molecule-link/MolPort-044-183-470
MolPort	MolPort-044-560-298	https://www.molport.com/shop/molecule-link/MolPort-044-560-298
Molnova	M11677	https://www.molnova.com/en/serch-list.html?keywords=M11677
Molnova	M17707	https://www.molnova.com/en/serch-list.html?keywords=M17707
MuseChem	I001536	https://www.musechem.com/product/I001536.html
Selleck Chemicals	S7796	http://www.selleckchem.com/search.html?searchDTO.searchParam=S7796
TargetMol	T4418	https://www.targetmol.com/search?keyword=T4418
eMolecules	178527209	https://orderbb.emolecules.com/search/#?query=178527209
eMolecules	195316287	https://orderbb.emolecules.com/search/#?query=195316287
eMolecules	53745104	https://orderbb.emolecules.com/search/#?query=53745104
mcule	MCULE-2638334942	https://mcule.com/MCULE-2638334942/
mcule	MCULE-5538211330	https://mcule.com/MCULE-5538211330/

PubMed

Title	Date	PubMed
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.	2015 Jul 13	26175415
Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.	2016	26881714

Patents

Sample Use Guides

In Vivo Use Guide

GSK-2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK-2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.

Route of Administration: Oral

In Vitro Use Guide

1 uM GSK-2879552 inhibited SCLC cell lines growth

Name

Type

Language

GSK-2879552

Common Name

English

4-((4-((((1R,2S)-2-PHENYLCYCLOPROPYL)AMINO)METHYL)PIPERIDIN-1-YL)METHYL)BENZOIC ACID

Systematic Name

English

BENZOIC ACID, 4-((4-((((1R,2S)-2-PHENYLCYCLOPROPYL)AMINO)METHYL)-1-PIPERIDINYL)METHYL)-

Systematic Name

English

GSK 2879552 [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

66571643